VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS, OTC: HYDTF, FSE: SO6) (“Hydreight” or the “Company”), a leader in nationwide digital healthcare solutions, is pleased to announce that it has closed its previously announced private placement of unsecured convertible debentures (the “Offering”). Canaccord Genuity Corp. acted as lead agent and sole bookrunner, for and on behalf of a syndicate of agents which included Beacon Securities Ltd. (collectively t ...

Core Viewpoint - Hydreight Technologies Inc. has announced a private placement offering of up to C$10,000,000 in unsecured convertible debentures to support its digital healthcare solutions business [1][6] Group 1: Offering Details - The company has granted Canaccord Genuity Corp. an option to increase the offering size by up to C$1,500,000 [2] - The debentures will mature 36 months from issuance and are convertible into common shares at a price of C$4.06 per share [3] - The offering is expected to close around September 4, 2025, pending regulatory approvals [6] Group 2: Financial Terms - The debentures will bear a fixed interest rate of 9.0% per annum, payable semi-annually [5] - The company will pay a cash commission of 6.0% to the lead agent and issue compensation warrants equal to 6.0% of the number of shares issuable upon conversion [7] Group 3: Company Overview - Hydreight Technologies Inc. is building a large mobile clinic network in the U.S., with over 2,500 nurses and 100 doctors across 50 states [10] - The company's platform includes integrated tools for healthcare professionals to provide services directly to patients [10]

Core Insights - Hydreight Technologies Inc. has reported record-breaking growth in orders for its VSDHOne platform, with July orders significantly exceeding projections and August tracking ahead of schedule towards a goal of 1.3 million total orders for 2025 [2][4] - The partnership with Perfect Scripts and the introduction of 503B compounding capabilities are expected to enhance the scalability, efficiency, and reach of the VSDHOne platform [4][7] - The launch of Hydreight Marketing Solutions aims to drive client growth and increase order volume across the VSDHOne network by providing marketing services tailored for healthcare providers [8][9] Order Growth - VSDHOne platform achieved approximately 7,187 SKU orders in June 2025, surpassing the internal forecast of 7,000–10,000 SKU orders [6] - In July 2025, the platform achieved approximately 35,642 SKU orders, over three times the internal forecast of around 10,000 SKU orders [6] - The internal forecast for August 2025 aims for approximately 55,000 SKU orders [6] Technology and Integration - Hydreight is enhancing the VSDHOne technology platform into a fully modular architecture, allowing businesses to adopt only the necessary components for order generation [3] - Perfect Scripts' technology integrates directly with VSDHOne, automating prescription processing and significantly reducing fulfillment times [7] - The 503B compounding capability allows Hydreight to manufacture and ship high-demand medications at scale, overcoming the limitations of traditional compounding methods [7] Marketing Solutions - Hydreight Marketing Solutions will provide data-driven campaigns and patient acquisition strategies specifically for healthcare providers on the VSDHOne platform [8] - The initiative is expected to drive significant growth, as successful marketing at the client level translates to higher patient volumes and order growth across the network [9] - The goal is to empower partners to market effectively, increasing patient engagement and revenue for all involved [9] Corporate Update - Gabi Kabazo has resigned as a director effective August 8, 2025, to focus on other professional commitments [10] - Hydreight Technologies Inc. has been recognized as the 56th fastest-growing company in North America on the 2024 Deloitte Technology Fast 500™ [11]

Hims & Hers Health Today HIMS Hims & Hers Health $55.46 -7.89 (-12.45%) 52-Week Range $13.47 ▼ $72.98 P/E Ratio 69.33 Price Target $39.83 Add to Watchlist Hims & Hers' NYSE: HIMS August price dip is an opportunity to buy, but investors shouldn't rush to get into this healthcare stock. Forces in play, including high short interest and tepid analyst involvement, are capping gains in 2025 and setting this market up for correction. The question is how deep the correction will get and when the rebound will begin ...

Key Takeaways HIMS reached 2.4 million subscribers in Q1 2025, with over 1.4 million using personalized health solutions.A new CTO hire and $870 million in funding will boost HIMS' AI strategy and global expansion efforts.HIMS is integrating pharmacy and diagnostics to control fulfillment and care quality at scale.The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS) , is building a next-generation, digital-first healthcare platform centered around personalization, accessibility and sca ...

Core Viewpoint - The integration of technology into various sectors is driving consumer growth in China, with significant advancements in healthcare, elderly care, smart home solutions, and immersive cultural tourism experiences [1][11]. Group 1: Internet Healthcare - The "Zijing AI Doctor" system, launched by Tsinghua University, features 42 AI doctors covering over 300 diseases, achieving a diagnostic accuracy of 93.06% for respiratory diseases [2]. - By the end of 2024, the number of internet healthcare users in China is expected to reach 418 million, accounting for 37.7% of internet users [2]. - The internet hospital market is projected to exceed 1.2 trillion yuan by 2030, representing 15% of total medical expenditure, with AI doctors involved in 80% of initial diagnoses [3]. Group 2: Smart Elderly Care - The aging population in China, with over 300 million individuals aged 60 and above, is creating opportunities for the silver economy, driven by technological innovations in elderly care [4]. - Sales of elderly care services increased by 65.5% in the first quarter of this year, while health monitoring devices saw a 41.6% rise in sales [5]. - The adoption of AI and IoT technologies is transforming elderly care from passive to active engagement, enhancing the quality of life for seniors [5]. Group 3: Smart Home Solutions - Haier's innovations in smart home appliances, such as AI-powered range hoods, are setting new standards in the industry, with over 113,000 patents filed globally [7]. - The market for digital smart home appliances is expanding, with exports of home appliances increasing by 6.1% in early 2025 [8]. - The trend towards full-home digitalization is expected to cover over 90% of new residential buildings in the next decade [8]. Group 4: Immersive Cultural Tourism - The digital Dunhuang platform allows users to experience ancient murals in high definition, showcasing the potential of technology in cultural tourism [10]. - The immersive tourism market is projected to generate significant revenue, with innovative experiences like AR and VR enhancing visitor engagement [11]. - The integration of technology in cultural tourism is expected to lead to highly customized experiences, aligning with consumer preferences [11].

Core Points - Equasens Group announces the departure of Damien Valicon as Deputy Chief Executive Officer and Director of the Pharmagest Division, with François-Pierre Marquier appointed as his successor [2][3] - François-Pierre Marquier has been with Pharmagest since May 2021 and has held various leadership roles, including overseeing the Pharmacy France business since January 2023 [4] - The transition period for François-Pierre Marquier's appointment will be effective after approval from the Board of Directors [3] Company Overview - Equasens Group, founded over 35 years ago, is a leader in digital healthcare solutions, employing over 1,400 people across Europe [6] - The company specializes in business applications that support healthcare professionals in their daily operations, including electronic equipment, digital solutions, and healthcare robotics [7] - Equasens Group aims to improve coordination among healthcare professionals through interoperability solutions, enhancing patient care and system efficiency [8] Strategic Direction - The company follows a two-pronged development strategy that combines organic growth with targeted acquisitions at a European level [9] - Upcoming financial communications include Q2 2025 revenue on July 31, 2025, and H1 2025 results on September 26, 2025 [11]

Core Points - The Ordinary Annual General Meeting of Equasens Group was held on June 25, 2025, with a quorum of 88.83% of shares with voting rights present [1] - The meeting approved the separate parent company and consolidated financial statements for the 2024 financial year [1] Voting Results Summary - **Resolution One**: Approval of the annual financial statements received 13,170,684 votes in favor, with no votes against and 2,441 abstentions [1] - **Resolution Two**: Discharge of directors and Statutory Auditors received 12,831,312 votes in favor, 339,266 votes against, and 2,547 abstentions [1] - **Resolution Three**: Approval of the consolidated financial statements received 13,170,684 votes in favor, with no votes against and 2,441 abstentions [1] - **Resolution Four**: Appropriation of earnings and setting the dividend received 13,138,631 votes in favor, 34,494 votes against [1] - **Resolution Five**: Agreements and commitments under Articles L. 225-38 received 13,101,211 votes in favor, 59,549 votes against, and 12,365 abstentions [2] - **Resolution Six**: Approval of compensation information for corporate officers received 12,507,815 votes in favor, 665,242 votes against, and 68 abstentions [2] - **Resolution Seven**: Approval of compensation for Mr. Thierry Chapusot received 13,115,547 votes in favor, 57,510 votes against, and 68 abstentions [2] - **Resolution Eight**: Approval of compensation for Mr. Denis Supplisson received 10,782,118 votes in favor, 2,390,939 votes against, and 68 abstentions [2] - **Resolution Nine**: Approval of compensation for Mr. Grégoire de Rotalier received 10,782,118 votes in favor, 2,390,939 votes against, and 68 abstentions [2] - **Resolution Ten**: Approval of compensation for Mr. Damien Valicon received 10,762,253 votes in favor, 2,410,804 votes against, and 68 abstentions [2] - **Resolution Eleven**: Approval of the compensation policy for Mr. Thierry Chapusot for 2025 received 13,115,547 votes in favor, 57,510 votes against, and 68 abstentions [3] - **Resolution Twelve**: Approval of the compensation policy for Mr. Denis Supplisson for 2025 received 10,545,572 votes in favor, 2,454,875 votes against [3] - **Resolution Thirteen**: Approval of the compensation policy for Mr. Grégoire de Rotalier for 2025 received 10,537,207 votes in favor, 2,463,240 votes against, and 172,678 abstentions [3] - **Resolution Fourteen**: Approval of the compensation policy for Mr. Damien Valicon for 2025 received 10,537,207 votes in favor, 2,463,240 votes against, and 172,678 abstentions [3] - **Resolution Fifteen**: Approval of the compensation policy for Directors received 13,127,845 votes in favor, 45,212 votes against, and 68 abstentions [3] - **Resolution Sixteen**: Setting total annual compensation for Directors for 2025 received 13,127,845 votes in favor, 45,212 votes against, and 68 abstentions [3] - **Resolution Seventeen**: Authorization to repurchase own shares received 11,297,178 votes in favor, 1,875,947 votes against [3] - **Resolution Eighteen**: Powers for formalities received 13,173,125 votes in favor, with no votes against or abstentions [3] Company Overview - Equasens Group, a leader in digital healthcare solutions, employs over 1,300 people across Europe and has been in operation for over 35 years [4][5] - The company specializes in providing applications that support healthcare professionals, including electronic equipment, digital solutions, and healthcare robotics [5][6] - Equasens Group is listed on Euronext Paris and included in various indexes such as MSCI GLOBAL SMALL CAP and CAC SMALL [7]

Core Points - Equasens Group will hold its Annual Ordinary General Meeting on June 25, 2025, at 5:30 PM at its registered office in Villers-lès-Nancy [2] - The agenda and resolutions for the meeting were published in the French legal announcements on May 16, 2025 [3] - The Meeting Notice was published on June 6, 2025, detailing participation and voting procedures [4] Company Information - Equasens Group, founded over 35 years ago, is a leader in digital healthcare solutions, employing over 1,300 people across Europe [8] - The company provides specialized business applications that support healthcare professionals in various settings, including private practice and healthcare establishments [9] - Equasens Group focuses on interoperability solutions that enhance coordination among healthcare professionals, improving patient care and system efficiency [10] Meeting Logistics - The Annual General Meeting will be broadcast live online, with connection information available 48 hours prior to the meeting [7] - A replay of the meeting will also be accessible on the company's website for later viewing [7] - All relevant documents and voting forms are available on the company's website since June 4, 2025 [5]

Core Viewpoint - Hims & Hers Health Inc. is seen as a promising growth story, combining technology sector growth with medical sector stability, offering investors significant upside potential [1] Company Overview - Hims & Hers Health's current stock price is $53.78, with a 52-week range between $13.47 and $72.98, and a P/E ratio of 122.23 [2] - The price target for the stock is set at $38.00, indicating a potential downside of 29.34% from the current price [11] Recent Developments - The company announced an acquisition of a European company named Zava, aiming to expand its operations in the European digital healthcare market [4] - Following the acquisition announcement, the stock initially rose but subsequently fell by 5.5% within a week, raising investor concerns [3][4] Market Sentiment - There are concerns regarding the regulatory environment in Europe, which may delay potential shareholder rewards from the acquisition [5] - The geopolitical tensions between the European Union and the United States, particularly regarding trade tariffs, could negatively impact investor sentiment [6][7] Financial Implications - The all-cash acquisition will affect the company's valuation, leading to a reassessment of the stock's price, which may currently be considered too high at approximately $53 per share [8] - Historical trading volumes suggest that a more sensible price level for the stock could be around $30-$32 per share, where institutional investors may be looking to re-enter [9][10] Analyst Ratings - Analysts currently hold a "Hold" rating on Hims & Hers Health, with some suggesting a valuation target as low as $30 per share, reflecting the potential short-term risks associated with the acquisition [12][11] - Despite the bearish outlook, the company continues to demonstrate strong growth rates and profitability, indicating potential for a favorable risk-to-reward ratio in the future [12][13]